Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.08 Analyst target: $18.83 Upside: 805.29%
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The company is headquartered in Westlake Village, California.
See the full interactive analysis & chart →Informational only — not investment advice.